Q32 Bio
- Founded: 2017
- Location: Cambridge, MA
- Employee range: 11 - 50
- Clinical stage: Clin2
- Therapy area: Atopic dermatitis
- Drug types: DRM, IMM
- Lead product: ADX-914 (partner: Horizon)
- Product link: https://www.q32bio.com/our-pipeline/
- Funding: $60M B Oct 2020; $46M A May 2020
q32bio.com linkedin.com job board
Short description:
Biologics to restore healthy immune regulation
Drug notes:
ADX-097 Clin1 complement driven disorders; 2 undisclosed programs RD/Clin0 complement driven disorders
Long description:
Q32 Bio is developing therapeutics to target regulators of the innate and adaptive immune systems. Immune dysregulation is a feature and driver of several diseases. Q32 Bio is creating antibody-based therapeutics that can modulate these systems and restore homeostasis in diseased tissues. This includes their program for IL-7, a cytokine that drives pathogenic T-effector cell expansion in autoimmune diseases and their unique approach to targeting the complement system. The complement system is an integral part of the innate immune system and Q32 Bio has devised an innovative solution to complement-mediated diseases by targeting their drugs directly to the affected tissue, while allowing other important functions of the complement to remain unimpaired.
Jobs:
© 2024 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com